| | | |   | | | | By Adam Feuerstein Andy Wong/AP Still, the new data show lung cancer patients are not benefiting from Lumakras as much as previously hoped. Read More | | By Sarah Owermohle White House photo Wegrzyn currently works at Boston-based Ginkgo Bioworks but has experience in two government agencies Biden hopes to emulate with ARPA-H. Read More | | By Ryan Cross — The Boston Globe Courtesy Tslil Ast Mootha Laboratory The company is developing treatments for diseases caused by broken mitochondria — the main energy source for human cells. Read More | | Sponsor content by ICON CLINICAL RESEARCH Maintaining the momentum in cell and gene therapy development In 2022, there are at least 11 CGTs pending approval in the US and six in the EU – how can drug developers maintain the momentum? Now is the time to lay the technical, regulatory, inancial and logistical foundations that will embed CGTs as a pivotal element of forward- looking health provision in years to come. Download this in-depth CGT whitepaper to gain insights on its current market state to practicalities of clinical trials through long-term commercialisation. | | By Bob Herman Adobe Longtime policy experts say Medicare relies too much on a self-interested, secretive panel of physicians to determine the profession’s pay. Read More | |
No comments